MDT

84.7

+0.83%↑

VEEV

231.57

+2.63%↑

A

107.51

+0.6%↑

WBA

10.91

-0.46%↓

CHE

575.22

+1.75%↑

MDT

84.7

+0.83%↑

VEEV

231.57

+2.63%↑

A

107.51

+0.6%↑

WBA

10.91

-0.46%↓

CHE

575.22

+1.75%↑

MDT

84.7

+0.83%↑

VEEV

231.57

+2.63%↑

A

107.51

+0.6%↑

WBA

10.91

-0.46%↓

CHE

575.22

+1.75%↑

MDT

84.7

+0.83%↑

VEEV

231.57

+2.63%↑

A

107.51

+0.6%↑

WBA

10.91

-0.46%↓

CHE

575.22

+1.75%↑

MDT

84.7

+0.83%↑

VEEV

231.57

+2.63%↑

A

107.51

+0.6%↑

WBA

10.91

-0.46%↓

CHE

575.22

+1.75%↑

Search

MacroGenics Inc

Închisă

SectorSănătate

1.6 -3.03

Rezumat

Modificarea prețului

24h

Curent

Minim

1.58

Maxim

1.65

Indicatori cheie

By Trading Economics

Venit

-72M

-15M

Vânzări

-93M

18M

P/E

Medie Sector

38.83

57.333

EPS

-0.818

Marjă de profit

-86.977

Angajați

341

EBITDA

-71M

-12M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+265.85% upside

Dividende

By Dow Jones

Următoarele câștiguri

8 mai 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-100M

88M

Deschiderea anterioară

4.63

Închiderea anterioară

1.6

Sentimentul știrilor

By Acuity

50%

50%

181 / 382 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Strong Bullish Evidence

MacroGenics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

29 apr. 2025, 23:53 UTC

Acțiuni populare

Stocks to Watch: Starbucks, Snap, Super Micro Computer, Seagate Technology

29 apr. 2025, 23:06 UTC

Câștiguri

Prudential PLC 1Q New Business Profit Increases by 12%

29 apr. 2025, 23:00 UTC

Câștiguri

America Movil's Posts Rise in 1Q Profit, Revenue

30 apr. 2025, 00:00 UTC

Top știri

Buffett's 'Woodstock for Capitalists' Draws Admirers From Around the Globe -- WSJ

29 apr. 2025, 23:46 UTC

Market Talk

Nikkei May Rise as Fears About U.S. Tariffs Ebb -- Market Talk

29 apr. 2025, 23:43 UTC

Market Talk

Gold Consolidates; Signs of Easing in U.S. Tariffs' Impact May Weigh -- Market Talk

29 apr. 2025, 23:41 UTC

Câștiguri

China Minsheng Banking 1Q Net Interest Income CNY24.87B Vs. CNY24.26B>1988.HK

29 apr. 2025, 23:41 UTC

Câștiguri

China Minsheng Banking 1Q Operating Income CNY36.81B Vs. CNY34.27B>1988.HK

29 apr. 2025, 23:41 UTC

Câștiguri

China Minsheng Banking 1Q Net CNY12.74B Vs. Net CNY13.45B >1988.HK

29 apr. 2025, 23:24 UTC

Câștiguri

China Vanke 1Q Rev CNY37.99B Vs. CNY61.59B >000002.SZ

29 apr. 2025, 23:24 UTC

Câștiguri

China Vanke: Increase in Investment Losses Also Hurt Results >000002.SZ

29 apr. 2025, 23:24 UTC

Câștiguri

China Vanke 1Q Loss CNY6.25B Vs. Loss CNY361.97M >000002.SZ

29 apr. 2025, 23:24 UTC

Câștiguri

China Vanke: Singificant Decline in Property Sales Weighed on Results >000002.SZ

29 apr. 2025, 23:24 UTC

Câștiguri

China Vanke 1Q Loss Widened Significantly >000002.SZ

29 apr. 2025, 23:15 UTC

Top știri

UPS to Cut 20,000 Jobs After Amazon Breakup -- 2nd Update

29 apr. 2025, 23:14 UTC

Câștiguri

China Eastern Airlines 1Q Loss CNY995.0M Vs. Loss CNY803.0M >0670.HK

29 apr. 2025, 23:14 UTC

Câștiguri

China Eastern Airlines: Increased Competition in the Aviation Market Hurt Results >0670.HK

29 apr. 2025, 23:14 UTC

Câștiguri

China Eastern Airlines 1Q Rev CNY33.41B Vs. CNY33.19B >0670.HK

29 apr. 2025, 23:14 UTC

Câștiguri

China Eastern Airlines 1Q Loss Widened >0670.HK

29 apr. 2025, 23:11 UTC

Câștiguri

China Southern Airlines Swung to Loss in 1Q>1055.HK

29 apr. 2025, 23:11 UTC

Câștiguri

China Southern Airlines 1Q Rev CNY43.41B Vs. CNY44.60B >1055.HK

29 apr. 2025, 23:11 UTC

Câștiguri

China Southern Airlines: Shift in Traveler Demographics, Competition From High-Speed Rail Networks Also Hurt Results >1055.HK

29 apr. 2025, 23:11 UTC

Câștiguri

China Southern Airlines 1Q Loss CNY747.0M Vs. Net CNY756.0M >1055.HK

29 apr. 2025, 23:11 UTC

Câștiguri

China Southern Airlines: CNY Depreciation, Global Supply Chain Constraints Among Factors Weighing on Results >1055.HK

29 apr. 2025, 23:07 UTC

Câștiguri

Air China 1Q Rev CNY40.02B Vs. CNY40.07B >0753.HK

29 apr. 2025, 23:07 UTC

Câștiguri

Air China 1Q Losses Widened>0753.HK

29 apr. 2025, 23:07 UTC

Câștiguri

Air China 1Q Loss CNY2.04B Vs. Loss CNY1.67B >0753.HK

29 apr. 2025, 23:02 UTC

Câștiguri

COSCO SHIPPING Energy Transportation: Weaker Earnings In International Oil Tanker Fleet Business Weighed on Results>1138.HK

29 apr. 2025, 23:02 UTC

Câștiguri

COSCO SHIPPING Energy Transportation 1Q Net CNY707.70M Vs. Net CNY1.24B >1138.HK

29 apr. 2025, 23:02 UTC

Câștiguri

COSCO SHIPPING Energy Transportation 1Q Rev CNY5.75B Vs. CNY5.84B >1138.HK

Comparație

Modificare preț

MacroGenics Inc Așteptări

Obiectiv de preț

By TipRanks

265.85% sus

Prognoză pe 12 luni

Medie 6 USD  265.85%

Maxim 8 USD

Minim 2 USD

În baza a 6 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruMacroGenics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

6 ratings

2

Cumpărare

4

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

1.64 / 1.79Suport & Rezistență

Termen scurt

Strong Bullish Evidence

Termen mediu

Bullish Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

181 / 382 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre MacroGenics Inc

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.